News | April 21, 2014

Robert Wood Johnson Treats Calcified Lesions Transradially

April 21, 2014 — Treatment options for high-risk heart patients with severely calcified coronary artery disease (CAD) have been limited for more than 20 years. Now, Robert Wood Johnson University Hospital (RWJUH) in New Brunswick, N.J., offers a new alternative to open up blocked arteries.

Plaque build-up in the arteries can form calcium lesions, and that build-up can be difficult to treat and significantly impact the quality of life of persons affected, explained Ramzan M. Zakir M.D., clinical assistant professor of medicine at Rutgers Robert Wood Johnson Medical School and director of transradial catheterization at RWJUH. For patients with lots of calcium in the arteries, it may be necessary to break up the calcium to allow the stents to open up or expand properly, he added.

“Although a device to break up calcium exists, that same device hasn’t really changed in over 20 years. It’s complex to use and involves a lengthy set-up time, leading some physicians to opt for open heart surgery to treat such blockages,” he said. “With the recently FDA-approved device called the Diamondback 360, we can easily break up the calcium to facilitate stent delivery and proper expansion. Even complex cases that previously could only be treated through the femoral artery now can be treated radially to restore proper blood flow and relieve patients’ symptoms such as chest pain and shortness of breath.”

Zakir has completed the required training, including six cases, for use of the Diamondback 360 Coronary Orbital Atherectomy System and is now the first physician in New Jersey to receive coronary certification from device maker Cardiovascular Systems Inc. (CSI).

This new, less invasive treatment alternative is significantly important for patients with severely calcified coronary artery disease that are considered high risk, including those managing other diseases (such as diabetes and chronic kidney disease) or the elderly, Zakir said.

CAD occurs when a fatty material called plaque builds up on the walls of arteries that supply blood to the heart. The plaque buildup causes the arteries to harden and narrow (atherosclerosis), reducing blood flow. CAD is a life-threatening condition and leading cause of death in men and women in the United States.

The risk of CAD increases if a person has one or more of the following: high blood pressure, abnormal cholesterol levels, diabetes, or family history of early heart disease. CAD affects an estimated 17 million people in the United States and is the most common form of heart disease, which claims more than 600,000 lives in the United States each year.

According to estimates, significant arterial calcium is present in nearly 40 percent of patients undergoing a percutaneous coronary intervention (PCI). Significant calcium contributes to poor outcomes and higher treatment costs in coronary interventions when traditional therapies are used, including a significantly higher occurrence of death and major adverse cardiac events.

Cardiovascular Systems Inc. received U.S. Food and Drug Administration (FDA) approval for the Diamondback 360 in October and RWJUH is one of only two hospitals in New Jersey using it.

For more information: www.csi360.com, www.rwjuh.edu

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init